← Leaderboards
Charles Sawyer
University Of California Los Angeles
$1,861,835
Attributed
$1,861,835
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $296.3K · FY2007–11$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,861,835 · 3
By mechanism
P50$1,447,303 · 1
M01$414,532 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Hong Wu$8,515,329
- Timothy Cloughesy$3,024,113
- Steven Grant Deeks$52,964,444
- Robert E Reiter$11,316,970
- Ardis A Moe$3,818,378
Others in their field
Top investigators on “Foxes”
- Robert C Young · Fox Chase Cancer Center$29,817,952
- David H Perlmutter · Washington University$18,341,120
- Paul F. Engstrom · Fox Chase Cancer Center$16,285,084
- Jose Russo · Fox Chase Cancer Center$13,662,143
- Jonathan D. Chernoff · Institute For Cancer Research$12,357,570
- Michael V. Seiden · Massachusetts General Hospital$12,156,089
Research focus
FoxesDoseEnrollmentFeedbackDesign1-Phosphatidylinositol 3-KinaseBiological ModelsEngineeringComplementEvaluationBaseCancer ModelCancer PatientCatalytic DomainCci-779CellsAnimalsConsensusBiopsyAblationClinical TrialsBloodCombined Modality TherapyFunding
Grant awards (8)
Exploiting PI3K Pathway Inhibitor Therapy in Prostate Cancer$281,515
P50 · FY2011 · CA · contact PI
Exploiting PI3K Pathway Inhibitor Therapy in Prostate Cancer$296,332
P50 · FY2010 · CA · contact PI
Exploiting PI3K Pathway Inhibitor Therapy in Prostate Cancer$296,266
P50 · FY2009 · CA · contact PI
Exploiting PI3K Pathway Inhibitor Therapy in Prostate Cancer$296,214
P50 · FY2008 · CA · contact PI
Exploiting PI3K Pathway Inhibitor Therapy in Prostate Cancer$276,976
P50 · FY2007 · CA · contact PI
CGP 57148B IN CHRONIC MYELOID LEUKEMIA PATIENTS$207,266
M01 · FY2001 · RR
CGP 57148B IN CHRONIC MYELOID LEUKEMIA PATIENTS$207,266
M01 · FY2001 · RR
TRIAL OF STI571 IN PATIENTS W/CHRONIC MYELOID LEUKEMIA$0
M01 · FY2001 · RR